Alcon Inc. (ALC): price, analyst ratings, earnings and fundamentals
Updated 16 September 2026, 08:02 ET
Alcon Inc. (ALC) closed at $67.76 on 15 September 2026, unchanged. The stock is down 8.7% over one month and down 13.4% over one year. It trades 22.7% below its 52-week high of $87.64. Analysts recorded 6 actions in the last 90 days; the median price target of $85 is 25.4% above the last close. The company last reported on 10 August 2026 for Q2 2026: EPS of $0.84 against an estimate of $0.76, a beat of 10.5%, on revenue of $2.8 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open ALC in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 6 analyst actions on ALC from 4 firms: 6 maintained or reiterated a view. Price targets were 3 raised and 1 lowered. The most recent targets from 7 firms range from $78 to $98, with a median of $85, 25.4% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 15 Sep 2026 | Needham | Reiterates Buy | $98.00 |
| 12 Aug 2026 | JP Morgan | Maintains Neutral | $77.53 to $78.40 |
| 12 Aug 2026 | Mizuho | Maintains Outperform | $80.00 to $85.00 |
| 11 Aug 2026 | Needham | Maintains Buy | $95.00 to $98.00 |
| 11 Aug 2026 | BTIG | Reiterates Buy | $82.00 |
| 15 Jul 2026 | Mizuho | Maintains Outperform | $85.00 to $80.00 |
| 8 May 2026 | Barclays | Maintains Equal-Weight | $90.00 to $78.00 |
| 7 May 2026 | Wells Fargo | Maintains Overweight | $97.00 to $86.00 |
| 7 May 2026 | Mizuho | Maintains Outperform | $95.00 to $85.00 |
| 7 May 2026 | Baird | Maintains Outperform | $98.00 to $90.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 10 November 2026 after the close for Q3 2026, with EPS expected at $0.88 on revenue of $2.8 billion. Alcon Inc. beat the EPS estimate in 5 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 10 Aug 2026 | $0.76 | $0.84 | +10.53% | $2.8B |
| Q1 2026 | 5 May 2026 | $0.81 | $0.85 | +4.94% | $2.7B |
| Q4 2025 | 24 Feb 2026 | $0.84 | $0.78 | -7.14% | $2.7B |
| Q3 2025 | 11 Nov 2025 | $0.82 | $0.79 | -3.66% | $2.6B |
| Q2 2025 | 19 Aug 2025 | $0.72 | $0.76 | +5.56% | $2.6B |
| Q1 2025 | 13 May 2025 | $0.77 | $0.73 | -5.19% | $2.5B |
| Q4 2024 | 25 Feb 2025 | $0.71 | $0.72 | +1.41% | $2.5B |
| Q3 2024 | 12 Nov 2024 | $0.74 | $0.81 | +9.46% | $2.4B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
On a trailing twelve month basis the company shows revenue growth of 4.94%, a gross margin of 55.85%, an operating margin of 13.08% and a return on equity of 4.50%.
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $1,527,000,000 |
| Inventory | $2,391,000,000 |
| Other Current Assets | $489,000,000 |
| Total Current Assets | $6,449,000,000 |
| Plant, Property & Equipment, Net | $4,774,000,000 |
| Goodwill Intangible Assets, Net | $9,006,000,000 |
| Deferred Tax Asset | $458,000,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Total Short-term Debt | $575,000,000 |
| Total Current Liabilities | $3,049,000,000 |
| Long-term Debt | $4,737,000,000 |
| Minority Interest | $1,000,000 |
| Other Liabilities | $40,000,000 |
| Total Liabilities | $9,520,000,000 |
| Total Stockholders Equity | $22,034,000,000 |
Figures as filed with the SEC for the period ended 31 December 2025, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 0.50 | 61st | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 2.12 | 70th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Equity | 0.24 | 51st | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Operational Leverage | -0.76 | 29th | Calculated as the ratio of Percentage change in EBIT / Percentage change in revenue. It is a measure of how earnings for the company is impacted by its sales activity. |
| Long Term Debt/Long Term Capital | 0.18 | 27th | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
| Long Term Debt/Total Capital | 0.17 | 27th | Calculated as (Short-Term Debt + Long-Term Debt / (Short-Term Debt + Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | -3.8% | 76th | The EBIT growth rate over the trailing twelve months (TTM) |
| EBIT Pct Growth 3 year CAGR | 26.5% | 36th | The EBIT compound annual growth rate (CAGR) over the past 3 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Free Cashflow Margin Pct | 16.6% | 77th | Calculated as the ratio of Free Cashflow from Operating Activities / Net Sales. It measures how much per dollar of revenue the company is able to convert into free cash flow. |
| Gross Margin Pct | 55.9% | 69th | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| Operating Margin Pct | 13.1% | 70th | Calculated as the ratio of (Revenue - (Cost of Goods Sold + Labour + Sales, General & Administrative)) / Revenue. Operating margins are important because they measure efficiency. The higher the operating margin, the more profitable a company's core business is. |
| Operating Profit Pct Growth | -3.8% | 41st | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | 26.5% | 80th | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| PreTax Margin Pct | 11.2% | 65th | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Equity Pct | 4.5% | 53rd | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 4.2% | 53rd | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| FCF Pct Growth | 7.7% | 50th | The Free Cash Flow growth rate over the trailing twelve months (TTM) |
| FCF Pct Growth 3 year CAGR | 197.4% | 85th | The Free Cash Flow compound annual growth rate (CAGR) over the past 3 years |
| FCF Pct Growth 5 year CAGR | 400.0% | 94th | The Free Cash Flow compound annual growth rate (CAGR) over the past 5 years |
| Operating Cashflow Pct Growth | 9.3% | 53rd | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 23.1% | 77th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 22.5% | 85th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | -3.7% | 40th | The Net Income growth rate over the trailing twelve months (TTM) |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 4.9% | 47th | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 6.1% | 54th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 8.8% | 56th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 15.5% | 58th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open ALC in FundSpec.
SEC filings
The latest filing is a 20-F from 24 February 2026.
| Filed | Form | Document |
|---|---|---|
| 24 Feb 2026 | 20-F | View on sec.gov |
| 25 Feb 2025 | 20-F | View on sec.gov |
| 27 Feb 2024 | 20-F | View on sec.gov |
| 27 Feb 2023 | 20-F | View on sec.gov |
| 15 Feb 2022 | 20-F | View on sec.gov |
| 23 Feb 2021 | 20-F | View on sec.gov |
| 25 Feb 2020 | 20-F | View on sec.gov |
| 18 Mar 2011 | 20-F | View on sec.gov |
| 16 Mar 2010 | 20-F | View on sec.gov |
| 17 Mar 2009 | 20-F | View on sec.gov |
Company profile
- Exchange
- NYSE
- Sector
- Medical Devices and Instruments
- Industry
- Medical Equipment
- Chief executive
- David J. Endicott
- Employees
- 25,200
- Website
- alcon.com
- SEC CIK
- 0001167379
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products. Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables. Vision Care segment provides daily disposable, reusable, reusable and color-enhancing contact lenses.
Sector and peers
Alcon Inc. is part of the Medical Devices and Instruments sector, which FundSpec tracks across 219 companies.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for ALC are available to subscribers, with the same screen in the iOS and Android apps.
Open ALC in FundSpec